Last reviewed · How we verify
Medium - High Influenza virus
At a glance
| Generic name | Medium - High Influenza virus |
|---|---|
| Sponsor | Hvivo |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Dose, Safety, and Pathogenicity of a New Influenza A H3N2 Challenge Strain (NA)
- Dose, Safety, and Pathogenicity of a New Influenza B Strain (PHASE2)
- Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers (PHASE1)
- Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults (PHASE1, PHASE2)
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults (PHASE2)
- Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population (PHASE2)
- Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Medium - High Influenza virus CI brief — competitive landscape report
- Medium - High Influenza virus updates RSS · CI watch RSS
- Hvivo portfolio CI